Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

ERK/MAPK Signalling Pathway Regulates MMP2 through ETS1 in Renal Clear Cell Carcinoma

Author(s): Hai-Bin Chen, Wei Li*, Zhan Yang*, Kai-Long Liu, Bao-Sai Lu and Zi-Yi Wang

Volume 24, Issue 6, 2024

Published on: 12 July, 2023

Page: [780 - 789] Pages: 10

DOI: 10.2174/1566524023666230529143837

Price: $65

Abstract

Background: The c-ETS-1 (ETS1) expression is high in clear cell renal cell carcinoma (ccRCC) tissues; however, how it impacts ccRCC is currently unknown.

Methods: The online STRING web source was used to construct a protein network interacting with ETS1. The Cell Counting Kit-8 was used to detect the cell viability. A clonogenic assay, a wound-healing assay, and a Transwell assay were used to detect cell proliferation, invasion and migration abilities. Western blot was used to detect the expression of proteins.

Results: The data showed the expression of ETS1 in ccRCC tissues to be significantly increased compared to adjacent tissues (p<0.05). The positive expression of ETS1 in ccRCC patients aged 20–100 was statistically significant compared to adjacent normal tissues (p<0.05). The grade of ETS1 positive expression (1-4) and lymph node metastasis (N1) in ccRCC were significantly higher than those in adjacent normal tissues (p<0.05). The tumour stage (stages 1-4) in ccRCC patients with positive ETS1 expression was significantly higher than that in adjacent normal tissues (p<0.05). Knockdown of ETS1 and PERK inhibitors significantly inhibited the proliferation, migration and invasion of ccRCC cells. Knockdown of ETS1 inhibited MMP-2 expression, and an extracellular signal-related kinase (ERK) inhibitor inhibited both ETS1 and MMP-2 expression.

Conclusion: A high expression of ETS1 is associated with the progression of ccRCC. This study suggests that ETS1 promotes proliferation by increasing MMP2 expression in ccRCC, and combined knockdown of ETS1 and inhibition of ERK can significantly inhibit the proliferation, migration and invasion of ccRCC. ETS1 may be a therapeutic and prognostic target for renal cell carcinoma.

« Previous Next »
[1]
Schrader AJ, Rustemeier J, Rustemeier JC, et al. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol 2009; 135(12): 1693-9.
[http://dx.doi.org/10.1007/s00432-009-0616-2] [PMID: 19543914]
[2]
Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin 2017; 67(6): 507-24.
[http://dx.doi.org/10.3322/caac.21411] [PMID: 28961310]
[3]
Grange C, Collino F, Tapparo M, Camussi G. Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol 2014; 4: 49.
[http://dx.doi.org/10.3389/fonc.2014.00049] [PMID: 24672771]
[4]
Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci 2021; 264: 118632.
[http://dx.doi.org/10.1016/j.lfs.2020.118632] [PMID: 33115605]
[5]
Tetsu O, McCormick F. ETS‐targeted therapy: An it substitute for MEK inhibitors? Clin Transl Med 2017; 6(1): 16.
[http://dx.doi.org/10.1186/s40169-017-0147-4] [PMID: 28474232]
[6]
Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: A literature review. World J Urol 2018; 36(12): 1943-52.
[http://dx.doi.org/10.1007/s00345-018-2309-4] [PMID: 29713755]
[7]
Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol 2021; 17(4): 245-61.
[http://dx.doi.org/10.1038/s41581-020-00359-2] [PMID: 33144689]
[8]
Hashiya N, Jo N, Aoki M, et al. In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109(24): 3035-41.
[http://dx.doi.org/10.1161/01.CIR.0000130643.41587.DB] [PMID: 15173033]
[9]
Vishnoi K, Viswakarma N, Rana A, Rana B. Transcription factors in cancer development and therapy. Cancers 2020; 12(8): 2296.
[http://dx.doi.org/10.3390/cancers12082296] [PMID: 32824207]
[10]
Yang X, Zhang Y, Fan H. Downregulation of SBF2-AS1 functions as a tumor suppressor in clear cell renal cell carcinoma by inhibiting miR-338-3p-targeted ETS1. Cancer Gene Ther 2021; 28(7-8): 813-27.
[http://dx.doi.org/10.1038/s41417-020-0197-4] [PMID: 32719443]
[11]
Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer 2017; 17(6): 337-51.
[http://dx.doi.org/10.1038/nrc.2017.20] [PMID: 28450705]
[12]
Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 1990; 346(6280): 191-3.
[http://dx.doi.org/10.1038/346191a0] [PMID: 2114554]
[13]
Watabe T, Yoshida K, Shindoh M, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998; 77(1): 128-37.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9] [PMID: 9639404]
[14]
Westermarck J, Seth A, Kähäri VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997; 14(22): 2651-60.
[http://dx.doi.org/10.1038/sj.onc.1201111] [PMID: 9178763]
[15]
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med 2020; 19(3): 1997-2007.
[http://dx.doi.org/10.3892/etm.2020.8454] [PMID: 32104259]
[16]
Sheng K, Wu Y, Lin H, et al. Transcriptional regulation of siglec-15 by ETS-1 and ETS-2 in hepatocellular carcinoma cells. Int J Mol Sci 2023; 24(1): 792.
[http://dx.doi.org/10.3390/ijms24010792] [PMID: 36614238]
[17]
Wen T, Barham W, Li Y, et al. NKG7 Is a T-cell–Intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy. Cancer Immunol Res 2022; 10(2): 162-81.
[http://dx.doi.org/10.1158/2326-6066.CIR-21-0539] [PMID: 34911739]
[18]
Sanyal S, Amin SA, Adhikari N, Jha T. Ligand-based design of anticancer MMP2 inhibitors: A review. Future Med Chem 2021; 13(22): 1987-2013.
[http://dx.doi.org/10.4155/fmc-2021-0262] [PMID: 34634916]
[19]
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci 2020; 21(24): 9739.
[http://dx.doi.org/10.3390/ijms21249739] [PMID: 33419373]
[20]
Zhang Q, Han Q, Yang Z, et al. G6PD facilitates clear cell renal cell carcinoma invasion by enhancing MMP2 expression through ROS-MAPK axis pathway. Int J Oncol 2020; 57(1): 197-212.
[http://dx.doi.org/10.3892/ijo.2020.5041] [PMID: 32319593]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy